1992
DOI: 10.1159/000247571
|View full text |Cite
|
Sign up to set email alerts
|

Disseminated Porokeratosis and Myelodysplastic Syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
11
0

Year Published

1994
1994
2006
2006

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 15 publications
(11 citation statements)
references
References 4 publications
0
11
0
Order By: Relevance
“…To our knowledge, this association of small bullae with DSAP has not been described previously. This bullous exacerbation was not associated with an immunosuppressive treatment [4], a malignant tumor [8, 9]or an autoimmune disease [10]. …”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…To our knowledge, this association of small bullae with DSAP has not been described previously. This bullous exacerbation was not associated with an immunosuppressive treatment [4], a malignant tumor [8, 9]or an autoimmune disease [10]. …”
Section: Discussionmentioning
confidence: 99%
“…Reed and Leone [20]have suggested that in a genetically predisposed individual, the disease results from the proliferation of abnormal clones of epidermal cells, which may be triggered by several stimuli, including sunlight or artificial UV light [18, 21, 22], exposure to electron beam radiotherapy [23], immunosuppressive treatments (as e.g. chemotherapy, immunosuppressive drugs or systemic corticosteroids) [4, 5, 6, 7, 8, 9, 10]or HIV infection [11]. A pathogenetic relationship between a latent virus infection and porokeratosis has been hypothesized, although never demonstrated.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…We present the second known case of PK in a patient with MDS. 10 On the basis of two case reports, the sudden appearance of disseminated PK does not necessarily justify the search for an underlying immunosuppressive disease. However, clinicians should be aware of the potential association, and patients should be evaluated in the appropriate clinical context.…”
Section: Discussionmentioning
confidence: 99%
“…Immunosuppression associated with malignancy and chemotherapy may exacerbate or initiate the development of porokeratosis in patients predisposed to alterations in eutaneous growth dynamics [43]. Mibelli's porokeratosis has been reported secondary to hepatic or renal transplantation [44,45] and Chernosky's porokeratosis has bee reported seeondary to immunosuppressors [46,47], plasmapheresis [48], pemphigus foliaceus treatment [49] and myelodysplastic syndrome [50].…”
Section: Discussionmentioning
confidence: 99%